Tregs CD25 CXCL9 in Vitiligo

NCT05569096 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-10-06

No results posted yet for this study

Summary

Clinical significance of circulating T regulatory cells , soluble CD25 and CXCL9 to assess disease activity of vitiligo.

Conditions

  • Vitiligo
  • CD25 Deficiency
  • Chemokine (C-X-C Motif)
  • Tregs

Interventions

DIAGNOSTIC_TEST

ELIZA , Flowcytometry

CD25 , CXCL9 by ELISA. T cell population , T regulatory cells by Flow cytometry.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2025-01-31
Completion
2026-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05569096 on ClinicalTrials.gov